<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1252">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545008</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100394</org_study_id>
    <nct_id>NCT04545008</nct_id>
  </id_info>
  <brief_title>Trial of Famotidine &amp; N-Acetyl Cysteine for Outpatients With COVID-19</brief_title>
  <official_title>A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Upstate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clemson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prisma Health-Upstate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety and toxicity profile of the combination of
      famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I trial enrolling subjects with newly diagnosed SARS-CoV-2 infection who do
      not require hospitalization. Exclusion criteria have been written to exclude patients who
      would be expected to have increased risk from either medication alone. Subjects will be
      assigned a dose combination of famotidine and n-acetyl cysteine. In addition to assessing the
      safety and toxicities profiles of the combination of drugs we will be measuring certain
      endpoints to assess possible efficacy. These endpoint include the following: rates of
      hospitalization; time to complete remission of symptoms, e.g, fever, respiratory symptoms,
      etc.; severity of symptoms with validated survey instruments; cytokine values in serum and
      urine; and markers of inflammation and oxidative stress.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>0 to 3 months</time_frame>
    <description>Data will be collected and entered into Case Report Form in local REDCap sever to include MedDRA Code, Grade and all other data required by NIH per Memorandum, &quot;Guidance for Collection of Adverse Events Related to COVID-19 Infection&quot; dated on 25 March 2020. All data will be reported per this memorandum and in accordance with all applicable Institutional Review Board and FDA requirements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalization</measure>
    <time_frame>0 to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptom Resolution</measure>
    <time_frame>0 to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Low Dose N-Acetyl Cysteine Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 600 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose N-Acetyl Cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,200 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose N-Acetyl Cysteine Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,800 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Oral Famotidine</description>
    <arm_group_label>High Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>High Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>High Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <other_name>Pepcid AC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetyl cysteine</intervention_name>
    <description>Oral N-Acetyl Cysteine</description>
    <arm_group_label>High Dose N-Acetyl Cysteine Alone</arm_group_label>
    <arm_group_label>High Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>High Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>High Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine Alone</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>Low Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and High Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Low Dose Famotidine</arm_group_label>
    <arm_group_label>Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  performance of a SARS-CoV-2 test within 1 day of enrollment, N.B., must be positive to
             proceed to treatment phase of the trial

        Exclusion Criteria:

          -  All patients under 18

          -  Known allergy to N-Acetyl Cysteine

          -  Known allergy to famotidine or other H2-receptor antagonists

          -  Pregnant or Nursing Mothers

          -  Laboratory Evidence or History of Renal Impairment (eGFR &lt; 30 mL/min/1.73 m2)

          -  Taking H2-receptor antagonists, hydroxychloroquine or chloroquine.

          -  Patient has been admitted to the hospital prior to study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John J O'Connell, M.D.</last_name>
    <phone>(864)679-3900</phone>
    <email>John.O'Connell@PrismaHealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Martin, DNP</last_name>
    <phone>(864)679-3900</phone>
    <email>Julie.Martin@PrismaHealth.org</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>outpatient</keyword>
  <keyword>famotidine</keyword>
  <keyword>n-acetyl cysteine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

